10 December 2020 
EMA/669235/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Veklury 
remdesivir 
On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Veklury. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted a change to the indication as follows:2 
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and 
adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring 
supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start 
of treatment). 
Detailed recommendations for the use of this product are described in the product information (PI), which 
is published in English here. 
The updated PI will be published in the revised European public assessment report (EPAR) in all official 
European Union languages after a decision on this change to the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
